Výsledky vyhledávání - "Elisa Lucchini"

Akademický článek

Serological and cellular response to mRNA-SARS-CoV2 vaccine in patients with hematological lymphoid malignancies: Results of the study 'Cervax'

Autor: Sara Mohamed, Elisa Lucchini, Francesca Sirianni, Marika Porrazzo, Laura Ballotta, Mario Ballerini, Giovanni Maria De Sabbata, Eleonora De Bellis, Ilaria Cappuccio, Marilena Granzotto, Barbara Toffoletto, Ilaria Fortunati, Anna Russignan, Emilia Elzbieta Florea, Lucio Torelli, Francesco Zaja

Publikováno v: Frontiers in Oncology, Vol 13 (2023)

messenger RNA (mRNA)-Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccines such as BNT162b2 became available in late 2020, but hematological malignancy patients (HM pts) were not evaluated in initial registration trials. We hereby repo

Externí odkaz: https://doaj.org/article/4745d20e03614202b13ffcceaf23b8c2

Zobrazit plný text záznamu

Akademický článek

Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy

Publikováno v: HemaSphere, Vol 6, Iss 12, p e798 (2022)

After FDA and EMA approval of the regimen containing polatuzumab vedotin plus rituximab and bendamustine (PolaBR), eligible relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients in Italy were granted early access through a Named Patient

Externí odkaz: https://doaj.org/article/1cc1af983bd1486091a4adbd8c7747a9

Zobrazit plný text záznamu

Akademický článek

Case report: Long-lasting SARS-CoV-2 infection with post-COVID-19 condition in two patients with chronic lymphocytic leukemia: The emerging therapeutic role of casirivimab/imdevimab

Autor: Laura Ballotta, Omar Simonetti, Pierlanfranco D’Agaro, Ludovica Segat, Raffaella Koncan, Pamela Martinez-Orellana, Federica Dattola, Emanuele Orsini, Alessandro Marcello, Simeone Dal Monego, Danilo Licastro, Andrea Misin, Sara Mohamed, Eugenio Sbisà, Elisa Lucchini, Giovanni Maria De Sabbata, Francesco Zaja, Roberto Luzzati

Publikováno v: Frontiers in Oncology, Vol 12 (2022)

Post-coronavirus disease 2019 (post-COVID-19) condition, previously referred to as long COVID, includes a post-acute syndrome defined by the presence of non-specific symptoms occurring usually 3 months from the onset of the acute phase and lasting at

Externí odkaz: https://doaj.org/article/536c0ab5cb9149988f1bd8145ebe5619

Zobrazit plný text záznamu

Akademický článek

Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi

Autor: Laura Ballotta, Pier Luigi Zinzani, Stefano Pileri, Riccardo Bruna, Monica Tani, Beatrice Casadei, Valentina Tabanelli, Stefano Volpetti, Stefano Luminari, Paolo Corradini, Elisa Lucchini, Maria Chiara Tisi, Michele Merli, Alessandro Re, Marzia Varettoni, Emanuela Anna Pesce, Francesco Zaja

Publikováno v: Frontiers in Oncology, Vol 11 (2021)

Patients with relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL) have a poor prognosis, with an expected survival of less than 1 year using standard salvage therapies. Recent advances in our understanding of the biology of PTCL have led to i

Externí odkaz: https://doaj.org/article/3dcd51666d87401a9cd59856a1eba1f0

Zobrazit plný text záznamu

Akademický článek

Immune checkpoint inhibitors in combination with radiotherapy as salvage treatment for relapsed/refractory classical Hodgkin lymphoma: A retrospective analysis in 12 patients

Autor: Elisa Lucchini, Chiara Rusconi, Mario Levis, Francesca Ricci, Armando Santoro, Umberto Ricardi, Stefano Volpetti, Fabio Matrone, Anna Di Russo, Manuela Caizzi, Anna Schiattarella, Francesco Zaja

Publikováno v: Hematology Reports, Vol 13, Iss 2 (2021)

The rate of complete remission (CR) with the anti-PD1 immune checkpoint inhibitors (ICI) nivolumab (N) and pembrolizumab (P) in patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) is low (20-30%), and the majority of patients eve

Externí odkaz: https://doaj.org/article/35964a569f1b49e1b155084f149ad497

Zobrazit plný text záznamu

Akademický článek

Case Report: Cardiac Involvement by Lymphoma: Rare but Heterogeneous Condition With Challenging Behaviors

Autor: Elisa Lucchini, Marco Merlo, Mario Ballerini, Aldostefano Porcari, Gianfranco Sinagra, Lorenzo Pagnan, Marco Rensi, Andrea Romano, Rossana Bussani, Laura Ballotta, Francesco Zaja

Publikováno v: Frontiers in Oncology, Vol 11 (2021)

Cardiac lymphomas are rare extranodal lymphomas involving primarily and secondarily the heart and/or pericardium. Here we describe three cases of cardiac involvement from lymphoma with specific peculiarities: two primary cardiac Diffuse Large B-cell

Externí odkaz: https://doaj.org/article/8cebabfadabe40199b0dbcb1c8460c03

Zobrazit plný text záznamu

Akademický článek

Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?

Autor: Elisa Lucchini, Francesco Zaja, James Bussel

Publikováno v: Haematologica, Vol 104, Iss 6 (2019)

The use of rituximab for the treatment of immune thrombocytopenia was greeted enthusiastically: it led to up to 60% response rates, making it, nearly 20 years ago, the main alternative to splenectomy, with far fewer side effects. However, long-term f

Externí odkaz: https://doaj.org/article/540a0b7fe36b4bd68f6c87d5bf2b0658

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání